The FDA has cleared Insulet's Omnipod Dash alternate controller-enabled infusion pump as an integrated insulin pump. The system can hold up to 200 units of U-100 insulin and features a touch-screen personal diabetes manager for control of the pod.

The British Columbia Ministry of Health has selected Insulet's OmniPod device as the preferred insulin pump in the Canadian province under its expanded PharmaCare insulin pump program. Coverage for the device will be given to eligible patients who request a replacement or initial insulin pump, according to the terms of the program.

Insulet has secured 510(k) clearance from the FDA for its Omnipod Dash insulin-management system, which allows the company's Personal Diabetes Manager to be wirelessly connected to its tubeless, waterproof insulin pump. The system, which will be released early next year in the US, also connects to the Omnipod View and Omnipod Display apps, allowing insulin therapy data to be accessed by caregivers and users.

Billerica, Mass.-based Insulet has tested its hybrid closed-loop OmniPod Horizon Automated Glucose Control System on the first patient enrolled in a feasibility study, which seeks to assess responses of 20 patients to the company's personalized Model Predictive Control algorithm. Insulet President and CEO Patrick Sullivan said the algorithm, designed to be integrated into the glucose control platform for treating type 1 diabetes, enables insulin control to be uninterrupted for up to 72 hours.

The FDA has granted Insulet Corporation approval for the new version of its OmniPod Insulin Management System, which features a smaller and lighter insulin pump and a Personal Diabetes Manager glucometer. The new system also calculates insulin on board.